Nootropics for Social Anxiety: Managing Cognitive Load (2026)

What Are Nootropics for Social Anxiety and How Do They Relate to Brain Chemistry?

Utilizing nootropics for social anxiety involves applying specific cognitive-enhancing substances to manage the neurobiological markers of social fear. Standard nootropics for social anxiety, such as L-theanine or Bacopa Monnieri, function by regulating neurotransmitter levels and reducing amygdala hyper-arousal, potentially lowering self-focused attention during social interaction while maintaining cognitive clarity in evaluative performance settings.

The term “nootropic” — coined by Romanian psychologist Corneliu Giurgea in 1972 — refers to any substance that enhances cognitive function while demonstrating low toxicity and minimal side effects. In the context of Social Anxiety Disorder, the relevant category is not cognitive stimulants (which can worsen social fear) but anxiolytic nootropics — substances that modulate GABAergic, serotonergic, or glutamatergic neurotransmission to reduce threat-circuit reactivity while preserving or enhancing cognitive performance.

This distinction is critical. The nootropic market is dominated by stimulant-based “focus” supplements containing high-dose caffeine, racetams, or amphetamine-adjacent compounds. For individuals with SAD, these substances can amplify the autonomic arousal that drives social anxiety symptoms — increasing heart rate, sweating, trembling, and hypervigilance rather than reducing them.

This guide evaluates only substances with demonstrated anxiolytic mechanisms relevant to the neurobiological profile of Social Anxiety Disorder. For FDA-approved pharmacological options with stronger evidence bases, see our guide on first-line pharmaceutical options.

The Neuroscience of “Smart” Anxiety Support

The Three Neurotransmitter Systems Relevant to Social Fear

Effective anxiolytic nootropics modulate one or more of the three neurotransmitter systems directly involved in social anxiety pathophysiology:

1. GABA (Gamma-Aminobutyric Acid) — The Inhibitory Brake

• GABA is the brain’s primary inhibitory neurotransmitter
• It reduces neuronal excitability throughout the central nervous system
• In SAD: GABAergic tone is often insufficient to counterbalance amygdala hyperactivation
• Substances that enhance GABA activity produce calming, anxiolytic effects
• Benzodiazepines work through this system (GABA-A receptor enhancement) — nootropic GABA modulators aim for similar but milder effects without addiction risk

2. Serotonin (5-HT) — The Mood and Threat Modulator

• Serotonin modulates emotional regulation, social cognition, and threat appraisal
• In SAD: serotonergic dysregulation contributes to persistent negative evaluation fear and amygdala hypersensitivity
• SSRIs are the first-line pharmaceutical treatment precisely because they enhance serotonergic transmission
• Nootropics with serotonergic activity aim to support this system through precursor supply or receptor modulation

3. Glutamate/NMDA — The Excitatory Signal

• Glutamate is the brain’s primary excitatory neurotransmitter
• Excessive glutamatergic activity contributes to neural hyperexcitability — racing thoughts, rumination, and difficulty disengaging from threat cues
• The glutamate-GABA balance determines overall neural excitability
• Substances that modulate glutamate activity — particularly through NMDA receptor regulation — can reduce the cognitive “noise” that amplifies social threat processing

What “Anxiolytic Nootropic” Actually Means

An anxiolytic nootropic is a substance that:

• Reduces autonomic arousal without producing sedation severe enough to impair cognitive performance
• Modulates threat-circuit reactivity — dampening amygdala response to social-evaluative cues
• Preserves or enhances cognitive function — attention, working memory, verbal fluency remain intact or improve
• Demonstrates low toxicity and minimal dependency potential
• Has at least preliminary human trial data supporting anxiolytic effects

This profile is narrow. Most marketed “nootropics” fail one or more of these criteria — either they produce no meaningful anxiolytic effect, or they achieve calm at the cost of cognitive impairment, or they lack human data entirely.

For the latest peer-reviewed evidence on anxiety neuroscience, see our guide on neuroscience research.

Editorial Note: The Paradox of Stimulants

The most popular nootropic category — cognitive stimulants — is often the worst choice for individuals with Social Anxiety Disorder.

The paradox: Stimulant nootropics (high-dose caffeine, modafinil, phenylpiracetam, adrafinil) enhance alertness, focus, and processing speed by increasing catecholaminergic neurotransmission — specifically norepinephrine and dopamine activity. For a neurotypical individual in a non-threatening environment, this produces improved cognitive performance.

For an individual with SAD, the same neurochemical shift produces a different outcome:

• Increased norepinephrine → heightened sympathetic nervous system activation → elevated heart rate, sweating, trembling, hypervigilance
• Increased dopamine → enhanced salience detection → social cues become more prominent, not less
• Increased cortical arousal → amplified self-focused attention → the “observer perspective” intensifies
• Caffeine specifically blocks adenosine receptors, removing the brain’s natural sedation mechanism → baseline anxiety escalates

The result: The person is cognitively “sharper” but physiologically and emotionally more reactive to social threat cues. They think faster — but the thoughts are anxious ones. They are more alert — but the alertness is directed at monitoring their own symptoms and others’ reactions.

Practical implication: Any nootropic stack for social anxiety must exclude or strictly limit stimulants. Caffeine intake above 100 mg is clinically inadvisable for individuals with moderate-to-severe SAD. The “focus and energy” marketed by most nootropic brands is precisely the neurochemical profile that exacerbates social fear [1][3].

For patients who experience both attention difficulties and social anxiety, the neurochemical balance is particularly complex. See our guide on ADHD and social anxiety overlap.

Top Rated Anxiolytic Nootropic Profiles

Comparative Overview: 5 Anxiolytic Nootropics for Social Anxiety

Parameter	L-Theanine	Magnesium L-Threonate	Ashwagandha (KSM-66)	Lion’s Mane (Hericium erinaceus)	Taurine
Chemical class	Amino acid (non-proteinogenic)	Mineral chelate	Adaptogenic herb (Withania somnifera)	Medicinal mushroom	Amino acid (sulfonic)
Primary mechanism	Glutamate modulation; alpha-wave promotion	NMDA receptor modulation; intracellular Mg²⁺	HPA axis regulation; cortisol reduction	NGF stimulation; neuroplasticity	GABA-A receptor modulation; glycine potentiation
GABA impact	Indirect — increases GABA levels via glutamate pathway	Indirect — Mg²⁺ is a natural NMDA antagonist, reducing excitatory tone	Mild — possible GABAergic activity via withanolides	Minimal direct effect	Direct — acts as GABA-A receptor agonist
Serotonin impact	Mild increase in serotonin levels	Indirect — Mg²⁺ supports serotonin synthesis	Moderate — modulates serotonergic pathways	Indirect — via BDNF and neuroplasticity	Minimal direct effect
Sedation level	None to minimal	None	Mild (dose-dependent)	None	Mild at higher doses
Cognitive effect	Enhanced alpha-wave activity; improved attention without drowsiness	Improved synaptic plasticity; enhanced learning and memory	Improved stress resilience; potential working memory benefit	Enhanced neuroplasticity; potential cognitive clarity	Neuroprotective; mild cognitive calming
Onset	30–60 minutes	2–4 weeks (requires loading)	2–6 weeks	4–8 weeks	30–60 minutes
Evidence quality for anxiety	Moderate — multiple human RCTs	Moderate — human trials for cognitive/anxiety	Moderate-strong — multiple RCTs for stress/anxiety	Low-moderate — primarily preclinical; limited human anxiety data	Low-moderate — human data emerging
Typical daily dose	200–400 mg	1,000–2,000 mg (144–288 mg elemental Mg)	300–600 mg (standardized extract)	500–1,000 mg	500–2,000 mg
Safety profile	Excellent; GRAS status	Excellent at recommended doses	Good; well-tolerated in RCTs	Good; well-tolerated	Excellent; naturally occurring in diet

Detailed Individual Profiles

1. L-Theanine (γ-Glutamylethylamide)

What it is: A non-proteinogenic amino acid found naturally in Camellia sinensis (green tea). Crosses the blood-brain barrier readily.

How it works in social anxiety:

• Alpha-wave promotion: L-theanine increases electroencephalographic alpha-wave activity — the brain state associated with relaxed alertness. This is the neurological opposite of the beta-wave dominance seen during anxious hypervigilance
• Glutamate modulation: Structurally similar to glutamate, L-theanine binds to glutamate receptors with weak affinity, partially blocking excitatory signaling without producing sedation
• GABA enhancement: Increases GABA levels indirectly, contributing to inhibitory tone
• Serotonin and dopamine: Modest increases in both neurotransmitters, supporting mood regulation

Evidence for social anxiety:

• Ritsner et al. (2011): L-theanine demonstrated anxiolytic effects in patients with schizophrenia-spectrum disorders — suggesting activity in populations with heightened social-evaluative sensitivity
• Hidese et al. (2019): Randomized controlled trial in healthy adults demonstrated reduced stress response and improved cognitive function under social stress conditions
• Kimura et al. (2007): L-theanine attenuated heart rate increase and salivary immunoglobulin A response during acute stress tasks [3]

Clinical application for SAD:

• Best for: Mild-to-moderate social anxiety; pre-event autonomic management; individuals who consume caffeine and want to counteract its anxiogenic effects
• Dosing: 200 mg taken 30–60 minutes before a social-evaluative situation. For daily use: 200–400 mg divided across morning and afternoon doses
• Combination note: L-theanine + low-dose caffeine (50–100 mg) is one of the most studied nootropic combinations — the theanine smooths the jittery activation of caffeine while preserving its alerting benefit
• Limitation: Effect is subtle. Insufficient as standalone management for moderate-to-severe SAD

2. Magnesium L-Threonate (Magtein)

What it is: A magnesium salt of L-threonic acid, specifically developed to enhance magnesium transport across the blood-brain barrier. Developed at MIT by researchers studying synaptic plasticity [4].

How it works in social anxiety:

• NMDA receptor modulation: Magnesium is a natural voltage-dependent NMDA receptor blocker. At adequate intracellular concentrations, Mg²⁺ prevents excessive glutamatergic excitation — reducing neural “noise” and threat-circuit hyperactivation
• Synaptic plasticity: Enhances synaptic density and plasticity in the prefrontal cortex and hippocampus — regions critical for threat regulation and contextual fear discrimination
• HPA axis regulation: Adequate magnesium status is associated with lower baseline cortisol — the stress hormone that primes the autonomic nervous system for social threat response
• Sleep quality: Magnesium deficiency is associated with insomnia and fragmented sleep — both of which compound social anxiety by reducing cognitive resilience

Evidence for anxiety:

• Slutsky et al. (2010): MIT research demonstrated that magnesium L-threonate was the only magnesium form that significantly elevated brain magnesium levels in animal models, enhancing learning and memory
• Boyle et al. (2017): Systematic review found that magnesium supplementation was associated with reduced subjective anxiety, particularly in populations with inadequate dietary magnesium intake
• National Institute on Aging has supported research on magnesium L-threonate for cognitive preservation [4]

Clinical application for SAD:

• Best for: Patients with suspected magnesium deficiency (common in Western diets); those with high baseline cortisol and sleep disruption; as a foundational supplement in a broader protocol
• Dosing: 1,000–2,000 mg magnesium L-threonate daily (providing approximately 144–288 mg elemental magnesium), typically divided into morning and evening doses
• Combination note: Pairs well with L-theanine for combined glutamate modulation and alpha-wave promotion
• Limitation: Requires 2–4 weeks of consistent dosing to reach effective brain concentrations. Not suitable for acute pre-event use

3. Ashwagandha (Withania somnifera — KSM-66 Extract)

What it is: An adaptogenic herb with a 3,000-year history in Ayurvedic medicine. KSM-66 is the most clinically studied standardized extract, containing a full-spectrum root preparation with consistent withanolide content.

How it works in social anxiety:

• HPA axis modulation: Ashwagandha’s primary anxiolytic mechanism is cortisol reduction. Multiple RCTs demonstrate significant decreases in serum cortisol levels with chronic supplementation — directly lowering the neurochemical driver of anticipatory anxiety
• GABAergic activity: Withanolides (the active compounds) demonstrate GABA-mimetic properties, contributing to inhibitory tone
• Serotonergic modulation: Evidence suggests modulation of 5-HT pathways, supporting mood regulation
• Adaptogenic normalization: Rather than producing a fixed pharmacological effect, adaptogens are theorized to normalize stress-response systems — dampening overactivation without producing sedation in non-stressed states

Evidence for anxiety:

• Lopresti et al. (2019): Double-blind RCT (n=60) demonstrated significant reductions in Hamilton Anxiety Rating Scale scores and serum cortisol with 240 mg KSM-66 daily over 60 days
• Chandrasekhar et al. (2012): RCT (n=64) showed significant reduction in all stress assessment scores and a 27.9% reduction in serum cortisol versus placebo with 300 mg twice daily [3]
• Salve et al. (2019): RCT demonstrating dose-dependent anxiolytic effects at 250 mg and 600 mg daily

Clinical application for SAD:

• Best for: Chronic baseline anxiety reduction; patients with elevated cortisol profiles; those seeking an adaptogenic approach alongside conventional treatment
• Dosing: 300–600 mg standardized KSM-66 extract daily, typically taken with a meal. Lower dose (300 mg) for general stress; higher dose (600 mg) for clinically significant anxiety
• Combination note: Pairs well with L-theanine for a non-sedating anxiolytic stack targeting both glutamate and cortisol pathways
• Limitation: Onset requires 2–6 weeks. Not suitable for acute pre-event use. Potential thyroid-stimulating effect — contraindicated in hyperthyroidism. May interact with sedative medications, immunosuppressants, and thyroid hormones

4. Lion’s Mane (Hericium erinaceus)

What it is: An edible medicinal mushroom that produces bioactive compounds — hericenones and erinacines — that stimulate Nerve Growth Factor (NGF) synthesis.

How it works in social anxiety:

• NGF stimulation: Hericenones (from fruiting body) and erinacines (from mycelium) cross the blood-brain barrier and promote NGF production — a neurotrophin critical for neuronal survival, growth, and synaptic plasticity
• BDNF support: Emerging evidence suggests Lion’s Mane may also support Brain-Derived Neurotrophic Factor (BDNF) — the neuroplasticity marker that increases during successful CBT treatment for anxiety disorders
• Anti-neuroinflammatory: Reduces neuroinflammation markers that are associated with chronic anxiety states
• Amygdala modulation: Preliminary animal data suggests reduction in anxiety-like behaviors through hippocampal neurogenesis — potentially improving contextual fear discrimination

Evidence for anxiety:

• Nagano et al. (2010): Small RCT (n=30) in menopausal women demonstrated reduced depression and anxiety scores after 4 weeks of Lion’s Mane supplementation
• Vigna et al. (2019): Human trial demonstrating improvements in mood and sleep quality with Hericium erinaceus supplementation
• Li et al. (2018): Preclinical evidence demonstrating anxiolytic effects mediated through hippocampal neurogenesis in animal models

Clinical application for SAD:

• Best for: Long-term neuroplasticity support; patients also engaged in CBT (where neuroplastic change is the therapeutic mechanism); those seeking cognitive clarity alongside anxiety management
• Dosing: 500–1,000 mg standardized extract daily (look for preparations standardized to beta-glucans and/or hericenones)
• Combination note: Pairs well with any other substance on this list — no significant interactions documented. The neuroplasticity mechanism complements the neurotransmitter-focused mechanisms of L-theanine, magnesium, and ashwagandha
• Limitation: Slowest onset of all substances reviewed (4–8 weeks). Evidence base for anxiety specifically is the weakest on this list — most data is preclinical or from small trials. Not suitable for acute management

5. Taurine (2-Aminoethanesulfonic Acid)

What it is: A sulfur-containing amino acid abundant in the brain, heart, and skeletal muscle. Not a building block of proteins but a critical neuromodulator.

How it works in social anxiety:

• Direct GABA-A receptor agonism: Taurine binds to GABA-A receptors, producing direct inhibitory neurotransmission — the same receptor family targeted by benzodiazepines, though with much lower binding affinity and no addiction potential
• Glycine receptor activation: Taurine also activates glycine receptors — another inhibitory receptor system — providing a secondary calming pathway
• Glutamate antagonism: Reduces excitatory glutamatergic transmission, lowering neural hyperexcitability
• Cell membrane stabilization: Taurine regulates calcium flux across neuronal membranes, contributing to overall neural stability

Evidence for anxiety:

• Kong et al. (2006): Demonstrated taurine’s anxiolytic effect in animal models mediated through GABA-A receptor activation
• Chen et al. (2019): Human data suggesting taurine supplementation reduces oxidative stress markers associated with chronic anxiety states
• El Idrissi et al. (2013): Neurochemical studies confirming taurine’s inhibitory neurotransmitter function and role in GABAergic modulation [3]

Clinical application for SAD:

• Best for: Acute pre-event calming (onset within 30–60 minutes); patients seeking a non-sedating GABA-modulating agent; those who cannot tolerate ashwagandha or prefer amino acid-based supplementation
• Dosing: 500–2,000 mg daily. For acute use: 1,000 mg taken 30–60 minutes before a social-evaluative situation. For chronic use: 500–1,000 mg twice daily
• Combination note: Pairs well with L-theanine for a fast-acting, non-sedating anxiolytic combination. The two amino acids target complementary pathways (glutamate modulation + GABA agonism)
• Limitation: Human evidence for anxiety specifically is limited. Most mechanistic data comes from preclinical models. Higher doses may produce mild drowsiness

Evaluating Your Autonomic Response and SAD Baseline

Why Supplementation Without Assessment Is Counterproductive

The nootropic substances reviewed above can provide meaningful support for mild social anxiety and pre-event autonomic management. However, they are categorically insufficient for moderate-to-severe Social Anxiety Disorder — a clinical condition requiring evidence-based treatment (CBT, SSRIs, or both).

The risk of self-treating with nootropics without clinical assessment:

• Undertreatment: A person with clinically significant SAD uses L-theanine and ashwagandha instead of seeking CBT — the disorder progresses while they believe they are “managing it”
• Misidentification: Symptoms attributed to “social stress” actually meet DSM-5-TR criteria for Social Anxiety Disorder — a treatable condition being managed with supplements instead of treatment
• Comorbidity blindness: Depression, GAD, ADHD, or panic disorder co-occurring with social anxiety may require specific pharmacological intervention that nootropics cannot provide

Substance optimization is most effective when grounded in a clear diagnosis. Use our evidence-based Social Anxiety Test to establish if your distress stems from clinical social phobia or situational fatigue. The test provides a severity score across fear, avoidance, and physiological dimensions — determining whether nootropics are an appropriate adjunct or whether professional treatment should be the primary pathway.

Decision Framework: Nootropics, Medication, or Therapy?

Nootropics may be appropriate when:

• ☐ Social anxiety is mild (LSAS < 30 / SPIN < 19) — below clinical threshold
• ☐ Anxiety is situational — limited to specific performance events, not generalized across social contexts
• ☐ The individual is already in CBT and seeking adjunctive physiological support
• ☐ First-line medications are declined, contraindicated, or being tapered with clinician guidance
• ☐ The primary goal is optimization of an already functional baseline, not treatment of a clinical disorder

Professional treatment is indicated when:

• ☐ Social anxiety is moderate to severe (LSAS > 60 / SPIN > 30)
• ☐ Avoidance is pervasive — affecting work, relationships, and daily activities
• ☐ Anxiety persists for six months or more with functional impairment
• ☐ Comorbid conditions are present (depression, GAD, substance use, ADHD)
• ☐ Previous supplement use has not produced meaningful improvement

For comprehensive treatment options, see our guide on behavioral interventions.

Stacking Protocols: Evidence-Based Combinations

Protocol 1: Pre-Event Acute Stack (Situational Performance Anxiety)

Target: Reducing autonomic arousal and cognitive hypervigilance before a specific social-evaluative event (presentation, meeting, date, interview).

Components:

• ☐ L-Theanine: 200 mg — 45 minutes before the event
• ☐ Taurine: 1,000 mg — 45 minutes before the event
• ☐ Optional: Low-dose caffeine (50 mg) if cognitive alertness is needed — only if caffeine does not exacerbate individual anxiety symptoms

Expected effect: Reduced heart rate variability toward calmer baseline, increased alpha-wave activity, reduced self-focused attention — without sedation or cognitive impairment.

Limitation: This is symptom management, not treatment. Repeated reliance on a pre-event stack without addressing the underlying fear cognitions through CBT creates a supplement-based safety behavior — the nootropic equivalent of holding a glass with two hands to hide trembling.

Protocol 2: Daily Baseline Stack (Chronic Mild Anxiety Reduction)

Target: Lowering the daily baseline of autonomic arousal, cortisol output, and cognitive reactivity to social threat cues.

Components:

• ☐ Ashwagandha (KSM-66): 300 mg — morning with food
• ☐ Magnesium L-Threonate: 1,000 mg — divided into 500 mg morning + 500 mg evening
• ☐ L-Theanine: 200 mg — afternoon (to sustain alpha-wave activity through the social portion of the day)
• ☐ Lion’s Mane: 500 mg — morning (long-term neuroplasticity support)

Expected effect over 4–6 weeks: Reduced baseline cortisol, improved stress resilience, enhanced synaptic plasticity in prefrontal regulatory circuits, mild reduction in anticipatory anxiety.

Limitation: This protocol may produce measurable improvement for subclinical or mild social anxiety. It is insufficient for moderate-to-severe SAD. If symptoms have not improved meaningfully after 6 weeks of consistent use, professional clinical evaluation is warranted.

Protocol 3: CBT Augmentation Stack (Therapy Support)

Target: Supporting the neuroplastic changes that occur during active CBT treatment — enhancing inhibitory learning during exposure therapy and cognitive restructuring.

Components:

• ☐ Lion’s Mane: 1,000 mg daily — maximizing NGF and BDNF support for neuroplasticity
• ☐ Magnesium L-Threonate: 1,000–2,000 mg daily — supporting synaptic plasticity and NMDA receptor function (relevant to inhibitory learning)
• ☐ L-Theanine: 200 mg taken before therapy sessions or exposure exercises — promoting relaxed alertness during therapeutic engagement

Rationale: CBT works through neuroplastic change — the brain forms new associations that compete with fear memories. Substances that support neuroplasticity (Lion’s Mane, Magnesium) and reduce the physiological barrier to exposure engagement (L-Theanine) may enhance the rate and durability of therapeutic learning.

Important caveat: This is a hypothesis supported by mechanistic reasoning and indirect evidence. No RCT has specifically tested these combinations as CBT augmentation agents for SAD. The protocol is speculative — grounded in neuroscience but not validated by direct clinical trial.

Safety, Interactions, and Contraindications

General Safety Considerations

• ☐ All five substances reviewed have favorable safety profiles at recommended doses in healthy adults
• ☐ None are controlled substances or carry addiction potential
• ☐ None produce withdrawal syndromes upon discontinuation
• ☐ Supplementation should be disclosed to your physician — particularly if you take prescription medications

Specific Contraindications and Interactions

L-Theanine:

• No significant drug interactions documented at standard doses
• Theoretically may enhance effects of antihypertensive medications (mild blood pressure reduction)
• Safe to combine with SSRIs, benzodiazepines, and beta-blockers

Magnesium L-Threonate:

• May reduce absorption of certain antibiotics (tetracyclines, fluoroquinolones) — separate dosing by 2 hours
• May interact with bisphosphonates (osteoporosis medications)
• High-dose magnesium can cause gastrointestinal effects (diarrhea, cramping)
• Caution with renal impairment — impaired magnesium excretion

Ashwagandha:

• Thyroid interaction: May increase thyroid hormone production — contraindicated in hyperthyroidism (Graves’ disease)
• Immunomodulatory: May stimulate immune activity — use with caution in autoimmune conditions or with immunosuppressant medications
• Sedative interaction: May potentiate sedative medications (benzodiazepines, antihistamines, sleep aids)
• Pregnancy: Insufficient safety data — avoid during pregnancy and breastfeeding
• Rare reports of liver injury with contaminated or high-dose products — use standardized extracts from reputable manufacturers

Lion’s Mane:

• No significant drug interactions documented
• Theoretical anticoagulant effect — caution with blood-thinning medications
• Generally very well tolerated; gastrointestinal discomfort reported rarely
• Allergic reactions possible in individuals with mushroom allergies

Taurine:

• May enhance effects of antihypertensive medications
• May interact with lithium (alters renal lithium excretion)
• Generally very well tolerated at recommended doses
• No significant interaction with SSRIs or benzodiazepines

Frequently Asked Questions

Clinical and Nutritional References

[1] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR). 5th ed., text revision. APA Publishing; 2022. Diagnostic criteria for Social Anxiety Disorder and treatment recommendations.

[2] Sarris, J., et al. (2013). “Plant-based medicines for anxiety disorders, Part 2: A review of clinical studies with supporting preclinical evidence.” CNS Drugs, 27(4), 301–319. Comprehensive review of adaptogenic and anxiolytic botanicals.

[3] Hidese, S., et al. (2019). “Effects of L-theanine administration on stress-related symptoms and cognitive functions in healthy adults: A randomized controlled trial.” Nutrients, 11(10), 2362. Published in Journal of Alternative and Complementary Medicine (related analyses).

[4] Slutsky, I., et al. (2010). “Enhancement of learning and memory by elevating brain magnesium.” Neuron, 65(2), 165–177. MIT research supported by the National Institute on Aging. Foundation for Magnesium L-Threonate development.

[5] Chandrasekhar, K., Kapoor, J., & Anishetty, S. (2012). “A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root.” Indian Journal of Psychological Medicine, 34(3), 255–262.

SocialAnxiety.co Clinical Editorial | socialanxiety.co | Clinically reviewed content does not replace individualized medical assessment. Nootropic supplements are not FDA-approved treatments for Social Anxiety Disorder. If social anxiety is significantly limiting your daily functioning, professional clinical treatment (CBT, SSRI medication, or both) offers the strongest evidence base for meaningful, lasting recovery. Nootropics may play a supportive role — but they are supplements, not substitutes.

Editorial Note: This article reviews the available scientific literature on nootropic substances with anxiolytic properties. The evidence base for most nootropics is substantially weaker than for FDA-approved medications and evidence-based psychotherapy. Content is intended for psychoeducation. It does not constitute medical advice. Nootropics are not FDA-approved treatments for Social Anxiety Disorder. Never substitute supplements for professional clinical care without physician supervision.